Table 1.
Treatment | Gender | DNA adducts/108 nucleotides (means ± SE) |
8-oxo-dGuo/105 nucleotides (means ± SE) |
---|---|---|---|
Sham | M | 2.0±0.16 | 1.7±0.16 |
F | 1.7±0.18 | 1.5±0.16 | |
M + F | 1.9±0.12 | 1.6±1.09 | |
AsA | M | 1.5±0.32 | 1.4±0.12 |
F | 1.5±0.21 | 1.3±0.10 | |
M + F | 1.5±0.18 | 1.4±0.08 | |
Naproxen | M | 1.9±0.15 | 1.5±0.16 |
F | 1.9±0.20 | 1.3±0.09 | |
M + F | 1.9±0.12 | 1.4±0.09 | |
ECS | M | 15.8±0.95a | 5.8±0.28b |
F | 16.6±0.84a | 5.8±0.37b | |
M + F | 16.2±0.61a | 5.8±0.22b | |
ECS + AsA | M | 7.3±0.59a,d | 3.2±0.33b,d |
F | 8.0±1.06a,d | 3.7±0.68b,c | |
M + F | 7.5±0.99a,d | 3.4±0.34b,d | |
ECS + Naproxen | M | 6.5±0.53a,d | 3.1±0.52b,c |
F | 7.4±1.09a,d | 4.0±0.43b,d | |
M + F | 7.0±0.59a,d | 3.6±0.35b,d |
The lungs of 10 mice per experimental group (five males and five females) were examined at the age of 10 weeks.
Statistical analysis: a P < 0.01 and b P < 0.001, as compared with the corresponding Sham; c P < 0.01 and d P < 0.001, as compared with the corresponding ECS.